SimAbs Raises €5 Million Series A to Scale Continuous GMP Manufacturing and expand current development for Antibodies and Biosimilars: Cells in, Drug Substance out.
Diepenbeek, BioVille, Belgium, December 18, 2025 – SimAbs is proud to announce the successful closing of a €5 million Series A financing round. This investment marks a major step in the company’s growth strategy and reinforces SimAbs’ ambition to transform antibody and biosimilar manufacturing through Full end-to-end continuous processing.
The Series A round brings together a mix of existing and new investors, combining strategic industrial insight with long term financial backing, underscoring strong confidence in SimAbs’ proprietary continuous manufacturing platform and its potential to reshape global biologics production. Existing investors also increased their commitments.
In addition, the broader investor syndicate reflects a strong international and industrially aligned shareholder base.
SimAbs will deploy the proceeds of the Series A to accelerate several strategic priorities:
- Upscaling its proprietary continuous GMP CDMO platform to 50 L manufacturing capacity.
- Advancing the development of a biosimilar preclinical data package.
- Establishing strategic partnerships to support long term growth.
- Further increasing commercial traction and revenue growth.
The company expects the latest platform to be up and running and approved by the Belgian Federal Agency by the end of the year, supporting its ambition to serve innovative and biosimilar antibody programs with a fully differentiated manufacturing approach.
SimAbs’ continuous manufacturing platform integrates high density perfusion upstream processing with continuous downstream purification. This enables significantly improved productivity, consistent product quality, reduced cost of goods, and a smaller manufacturing footprint compared to traditional fed batch processes. By eliminating large hold steps, stabilizing critical quality attributes such as glycosylation and full automatization, SimAbs positions itself as a next generation CDMO for antibody therapeutics. Cells in, Drug substance out.
Koen Dierckx, CEO of SimAbs, commented:
“This Series A financing validates our vision that continuous manufacturing is not only a technological improvement, but a necessary evolution for the biologics industry. We are grateful for the trust of our existing shareholders and proud to welcome new investors who share our belief that high quality antibody production must become more accessible, scalable and sustainable. This funding allows us to accelerate execution and bring our platform to the next level.”
SimAbs’ strategy is strongly aligned with the growing demand for affordable biologics and biosimilars worldwide. Continuous manufacturing enables lower production costs, faster technology transfer, and improved environmental sustainability through reduced resource consumption and smaller facility footprints. In an industry facing increasing cost pressure and global climate challenges, SimAbs’ approach combines economic efficiency with responsible manufacturing.
The company is currently engaging with multiple potential partners and customers, with plans to announce strategic collaborations in the coming weeks and months.
About SimAbs
Founded in 2019, SimAbs is a Belgium based contract development and manufacturing organization specializing in antibodies and biosimilars. Operating from its facilities in BioVille, Diepenbeek, the company develops and applies proprietary continuous manufacturing technologies covering cell line development, upstream and downstream process development, analytical development, and GMP manufacturing. SimAbs’ mission is to enable high quality, cost effective and sustainable production of antibody therapeutics.
For further information or press inquiries:
Website: https://www.simabs.com
Email: info@simabs.com